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g/10.1016Abstract Cancer is a leading cause of death worldwide. Interventional cancer therapy made huge
progress in the past few decades; however, traditional interventional therapy, for example, transar-
terial embolisation and transarterial chemoembolisation, remains to be developed for its potential
limitations. Numerous studies in the past half century demonstrated that tissue injury accelerated
after ischaemia reperfusion. Reactive oxygen species (ROS) production, cell death and inﬂamma-
tory factors involved in the development of ischaemia reperfusion injury. As outlined above, we
hypothesise that reperfusing the tumour lesion with high oxygen, high calcium and high pH ﬂuid
together with ROS-generating agents and/or inhibitor of antioxidant system, with or without
traditional chemotherapeutic agents after a short-time arterial embolisation, can effectively induce
cancer cell death, and it might be a new attempt in cancer interventional therapy.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd.Open access under CC BY-NC-ND license. Introduction
Cancer is a leading cause of death worldwide. Billions of dol-
lars were spent on exploring the effective strategy for cancer
treatment, but the output remains clearly dissatisﬁed. Tradi-
tionally, there are three pillars in the treatment of malignant
tumour: chemotherapy, radiotherapy and surgery. In the past
few decades, interventional therapy rapidly developed in very
early local cancer treatment and advanced cancer palliative
care for its obvious advantages such as minimal invasion [1].
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/j.jmhi.2012.03.003highly concentrated dose of chemotherapeutical drugs to tu-
mour tissues, to prolong the contact time between the drugs
and the tumour cells and to minimise systemic toxicity from
the chemotherapeutic agents [2]. Arterial chemotherapy and
lipiodolisation were earlier applied in clinical treatment of can-
cer, but they have nearly been replaced by transarterial embol-
isation (TAE) and transarterial chemoembolisation (TACE)
during the last decade, which was demonstrated by their effec-
tiveness proved by randomised clinical trials [2,3].
TAE is one of the most frequently used interventional ther-
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operatively or as a palliative means [1]. The mechanism of TAE
is induction of tumour ischaemia necrosis and programmed cell
death through blocking the tumour blood and oxygen supply.
TACE is an improved TAE and it refers to the same procedure
preceded by the administration of chemotherapeutic agents.
Although there exist controversial ﬁndings, more researchers
incline to support that effectiveness of TAE together with regio-
nal chemotherapy is better than simple arterial chemoperfusion
in cancer treatment [1,3]. However, recent data suggested that
hypoxia generated by arterial embolisation up-regulated vessel
endothelial growth factor (VEGF) and induced angiogenesis
that leads to tumour growth [4]. Moreover, studies have shown
that hypoxia mediates cancer cells resisting apoptosis [5,6].
Furthermore, by an unknown mechanism hypoxia is associated
with metastasis [7]. Therefore, it is necessary to improve TACE
or explore new methods of transarterial therapy.
In the 1960s, Jennings et al. reported that canine heart sub-
jected to coronary ligation showed reperfusion appearing to
accelerate the development of necrosis [8]. In the following half
century, ischaemia reperfusion injury (IRI) was profoundly
explored. Although the essential mechanisms remain unclear,
accelerated injury of ischaemic tissues after reperfusion is
unquestionable. Ischaemia leads to tissue acidosis and accumu-
lation of intracellular sodium, hydrogen and calcium ion.
Reperfusion elicits rapid renormalisation of intracellular so-
dium, hydrogen, calcium and hypoxia and consequently results
in the so-called oxygen paradox, calcium paradox and pH
paradox [9]. Molecular and cellular events such as reactive oxy-
gen species (ROS) production, cell death, leucocyte invasion and
innate immune reaction play critical roles in the development of
ischaemia reperfusion injury [9–11].
The hypothesis
Considering that ischaemia reperfusion may lead to injury in
normal organs, especially those with high metabolic rate, it is
reasonable to assume that ischaemia reperfusion can also lead
to tumour injury. Therefore, we hypothesise that reperfusing
the tumour lesion with high oxygen, high calcium concentra-
tion and high pH ﬂuid together with ROS-generating agents
and/or inhibitor of antioxidant system, with or without tradi-
tional chemotherapeutic agents after a short-time (60 min)
arterial embolisation, will be an effective candidate for inter-
ventional therapy for cancer treatment. Considering the
achievement done and the obstacles faced by tumour interven-
tional therapy, we believe that this is a totally new approach
that is worth attempting.
Evaluation of the hypothesis
Excessive amounts of ROS induce cancer cell death by directly
damaging membranes, DNA and proteins, and/or induce cell
apoptosis [12]. ROS as target in cancer treatment was widely
detected and believed to be a promising therapy [13,14]. Most
recently, Nature Review Drug Discovery published an article
claiming that targeting cancer cell by ROS-mediated mecha-
nism is probably a radical therapeutic approach [12]. Several
ROS-generating agents and inhibitors of antioxidant system
are currently in clinical trial [12,15–17]. Although a great
diversity of factors involved in the development of IRI, ROSgeneration was recognised as one of the most critical ones
[18]. Reperfusing ischaemic tumour tissue with perfusate con-
taining ROS-generating agents and/or inhibitors of antioxidant
system, with or without traditional chemotherapeutic drugs,
may theoretically induce more ROS generation and damage
tumour cells. Cancer stem cells (CSCs) are cancer cells that pos-
sess the characteristics associated with normal stem cells, and
CSCs may generate tumour by self-renewal and differentiation
[19]. CSCs are naturally resistant to chemotherapeutic agents
because of their slow rate of cell turnover, DNA repair protein
and various pumps that pump out drugs [20]. Recent research
found that CSCs show low ROS level, and pharmacological
depletion of ROS scavengers in CSCs markedly decrease their
clonogenicity and result in radiosensitisation. Overcoming low
ROS level of CSCs may be a promising approach for improving
local and systemic oncological therapies [21]. Moreover, cancer
cell mitochondria are structurally and functionally different
from their normal counterparts, thereby rendering them more
susceptible to mitochondrial perturbations than non-immorta-
lised cells [22]. Cell death occurs via necrosis and apoptosis after
ischaemia reperfusion.Mitochondria play a critical role in these
two distinct types of death [9,23]. Thereafter, we reason that
reperfusing tumour tissue after an appropriate ischaemia proce-
dure will induce effective cancer cell death.
Furthermore, up-regulated cytokine, activated innate
immunity, neutrophil accumulation and macrophage/T-cell-
mediated injury after ischaemia reperfusion are all involved
in cancer cell death [9,11].
Taken together, we assume that ischaemia reperfusion of tu-
mour tissue with ROS-generating agents and/or inhibitors of
antioxidant system, with or without traditional chemotherapeu-
tic drugs, could be more effective in treating cancer than both
simply transarterial embolisation and arterial chemotherapy.
Testing the hypothesis
We recommend the following procedure to test the hypothesis:
1. Establish malignant animal model. Abdominal viscera such
as liver or kidney cancers are goodmodels because they have
a single blood vessel supply and less collateral circulation
which facilitate ischaemia reperfusion. (95% blood supply
to primary hepatic carcinoma by hepatic artery, almost
100% blood supply to kidney cancer by renal artery).
2. Compare the outcomes between arterial embolisation
(ischaemia) and recanalisation after arterial embolisation
60 min (ischaemia reperfusion) in the following aspects:
A, tumour growth; B, tumour metastasis; C, survival rate;
D, biopsy detection of tumour cells death; E, radiosensitiv-
ity, chemosensitivity and operation opportunity.
3. Compare the outcomes between arterial embolisation and
reperfusion after arterial embolisation 60 min with ROS-
generating agents and/or inhibitors of antioxidant system,
with or without traditional chemotherapeutic drugs.
4. Evaluate the therapeutic effects in different ischaemia reper-
fusion times (300, 600, 900 and 1200) and frequencies 1, 2 and 4.
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52 Q. Duan, T. YangOverview BoxFirst Question: What do we already know about the
subject?
1. Ischaemia leads to tissue damage.
2. Tissue injury accelerated after ischaemia
reperfusion.
Second Question: What does your proposed theory
add to the current knowledge available, and what bene-
ﬁts does it have?
Ischaemia reperfusion may accelerate tumour tis-
sue injury. This hypothesis provides a new essay in tu-
mour treatment.
Third question: Among numerous available studies,
what special further study is proposed for testing the
idea?
The hypothesis can be tested conducting by animal
experiments. We can compare the outcomes of embol-
isation and recanalisation after arterial embolisation,
and then observe multiple end-point events including
tumour growth, metastasis and animal survival time,
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